Intranasal Scopolamine for Motion Sickness - PubMed
2019年11月1日 · INTRODUCTION: Rapid onset, noninjection methods are required to provide "as needed" therapy for motion sickness. Intranasal scopolamine (IN SCOP) is attractive because it can be fast acting and work when gastric motility is slowed. Intranasal administration can provide a time to maximal conce …
Intranasal Scopolamine Gets Priority Review for Motion Sickness …
2023年9月26日 · Pharmacokinetic studies also showed that scopolamine administered via an intranasal gel demonstrated rapid absorption, bringing the potential benefit of rapid onset of action.
DPI-386 (scopolamine): What is it and is it FDA approved ... - Drugs.com
2024年1月31日 · The intranasal gel formulation of scopolamine demonstrated rapid absorption in pharmacokinetic studies. Potential benefits include ease of use and rapid onset of action. The U.S. Food and Drug Administration (FDA) has accepted …
scopolamine have not been established, results from preliminary studies indicate intranasal scopolamine has faster absorption, higher bioavailability, and a more reliable therapeutic index than equivalent oral or transdermal forms.
The efficacy of low-dose intranasal scopolamine for motion
Introduction: Scopolamine is an effective motion sickness prophylactic, but oral and transdermal formulations are slowly absorbed. To enhance absorption and potentially efficacy, an intranasal formulation of scopolamine (INSCOP) was tested.
Bioavailability of intranasal scopolamine in normal subjects
The bioavailability of scopolamine in three dosage forms was compared in 12 healthy nonsmoking male volunteers. Subjects received 0.4-mg doses of scopolamine bromide in intravenous (i.v.), intranasal (i.n.), or oral (p.o.) dosage forms on three occasions, with at …
Intranasal scopolamine preparation and method - NASA …
1991年9月25日 · A new method and preparation for intranasal delivery of scopolamine provides a safe and effective treatment for motion sickness and other conditions requiring anticholinergic therapy. The preparation can be in the form of aqueous nasal drops, mist spray, gel or oinment.
scopolamine intranasal (Pending FDA Approval) - Medscape …
Medscape - Motion sickness dosing for scopolamine intranasal, frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost...
Defender Seeks Approval of Intranasal Scopolamine for Motion …
2023年7月28日 · The NDA for an intranasally administered scopolamine gel (DPI-386 nasal gel) has been submitted to the FDA for prevention of motion sickness.
Scopolamine nasal spray in motion sickness: a ... - ScienceDirect
2001年5月1日 · There were no signs for a nasal or epipharyngeal irritation of the mucous membrane. Scopolamine nasal spray was found to be an effective and safe treatment in motion sickness, with a fast onset of action within 30 min after administration.
- 某些结果已被删除